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Background: To assess clinical outcomes of transcatheter aortic valve implantation (TAVI) comparing Medtronic CoreValve ReValving System® with 
Edwards SAPIEN XT™. 
Methods: All consecutive patients in our center with aortic stenosis treated with transfemoral Medtronic CoreValve ReValving System® (MCV) from 
November 2009 to September 2011 (learning curve patients excluded) or Edwards SAPIEN XT™ (ESV) from April 2010 to September 2011 when the 
device became available were included.
Results: In total, there were 192 patients in this analysis. The overall mean age was 79.4±8.1 years, logistic EuroSCORE 21.1±15.9% and STS-
PROM score 8.8±8.6%. The MCV group consisted of a greater proportion of males (60.3% vs. 43.7%; p=0.026) with a corresponding larger aortic 
annulus size (24.7±2.0 vs. 23.4±1.7; p<0.001). The median clinical follow-up length was 171 (IQR 54-357) days. Thirty-day all cause mortality 
was 4.0%, myocardial infarction rate 1.0% and stroke 0.5%, with no differences between valve types. Life-threatening bleeding occurred in 14.7% 
and 11.5% had a major vascular complication. There were no differences in the combined safety endpoint at 30 days (ESV 72.2% vs. MCV 71.9%; 
p=0.936). However, there was a significantly higher rate of device success amongst the ESV group (98.3% vs. 90.4%; p=0.012) with additionally a 
significantly higher rate of conduction disturbances/arrhythmia (31.5% vs. 16.0%; p=0.011) as well as pacemaker implantation (28.8% vs. 5.0%; 
p<0.001) with MCV compared with ESV.
Conclusions: In our single center experience, TAVI was a relatively safe and effective procedure utilizing both commercially available devices. 
However, there was an increased incidence of arrhythmia and pacemaker implantation in the MCV group.
